Navigation Links
Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale
Date:10/8/2008

CALGARY, Oct. 8 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has successfully completed initial scale up of its manufacturing process for REOLYSIN(R) to commercial scale.

The scale up of primary production and downstream processing development was undertaken by the National Research Council Biotechnology Research Institute (NRC-BRI) located in Montreal, Canada.

"Our existing manufacturing capacity at 40 litres allows us to support future pivotal clinical studies with REOLYSIN(R)," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. "Using this process, a 100-litre manufacturing facility has the potential to produce more than one million doses a year for intravenous use."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the manufacturing process, the transfer of the scale up to full cGMP production, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and developme
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015 /PRNewswire/ - BioAmber Inc. ... sustainable chemicals, today announced that it has priced an underwritten ... at a price of $9.00 per share, and granted ... purchase up to an additional 585,000 shares of its ... be $35.1 million.  The offering is expected to close on ...
(Date:5/1/2015)... May 1, 2015 A new ... antithrombotic drugs will reach $22.4bn in 2019. That revenue ... Industry and Market Prospects 2015-2025 ,  published ... investigation is to provide forecasts and qualitative analyses of ... publisher and consultancy in London, UK ...
(Date:5/1/2015)... DALLAS , May 1, 2015 ... report "Antibody Production Market by Product (Equipment, Consumables), by ... (Biopharmaceutical Companies, Diagnostic Labs, Research Institutes) - Analysis ... the report studies the global Antibody Production Market ... This market is expected to reach $2.572 Billion ...
(Date:4/30/2015)... N.J. , April 30, 2015  Roka Bioscience, ... focused on providing advanced testing solutions for the detection ... results for the first quarter of 2015 on May ... Roka Bioscience will also host a conference ... 2015 to discuss its first quarter financial results. During ...
Breaking Biology Technology:BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2
... conducted at The,Walter and Eliza Hall Institute ... agreement signed between Australian biotechnology company,Bionomics, (ASX:BNO) ... the Development and Licensing Agreement, Merck Serono ... sclerosis (MS) and other autoimmune,conditions. These prospective ...
... University of Texas at San Antonio (UTSA) South Texas Center ... Science Center at San Antonio (UTHSCSA) have identified a cell ... infectious process against Francisella tularensis, a respiratory pathogen ... findings will be released this week in a journal article ...
... 1 To effectively measure,customer satisfaction, follow-up CSR ... of 5 among customer service and call center ... Practices, LLC,s GLOBAL,BENCHMARKING COUNCIL., However, only 35 ... in the study,s health care segment not using ...
Cached Biology Technology:MS Drug Development Agreement Based on WEHI's Medicinal Chemistry 2UTSA/UTHSCSA publish results on bio-threat agent 2Follow-up Phone Surveys: Effective Customer Service Assessment Tool for Improving Satisfaction 2
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
(Date:3/26/2015)... The Granite Club, ... club, today announced it has implemented a state-of-the-art access ... for members and staff, while restricting access to authorized ... selected FST,s IMID Access system because it has the ... and staff, in addition to unparalleled security," said ...
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... crash-car derby between heavy and light isotopes vying for the ... have an edge, research led by Case Western Reserve University ... igneous rocks form. As molten rock cools along a ... happens because hotter atoms move faster than cooler atoms and, ...
... release is available in German . ... increasing quantities as substitutes for CFCs, are also climatically very ... journal Science an international team of researchers recommends ... This could save the positive side effect of the Montreal ...
... An invasive plant may have saved an iconic Australian lizard ... according to research published in the March issue of The ... invasive species preparing local predators for the arrival of another, ... who led the research. Cane toads were ...
Cached Biology News:How heavy and light isotopes separate in magma 2How heavy and light isotopes separate in magma 3Protecting the climate by reducing fluorinated greenhouse gas emissions 2Protecting the climate by reducing fluorinated greenhouse gas emissions 3Invasive plant protects Australian lizards from invasive toad: Study 2
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Anti-gamma Glutamyl Transferase (gammaGT) Host: mouse monoclonal Species Reactivity: human Applications: WB, IP, FC Storage: 4C...
Biology Products: